Antioxidant Therapy in Graves' Orbitopathy.
Enalapril
Graves’ orbitopathy (GO)
N-acetyl-l-cysteine
Quercetin
Vitamin C
melatonin
oxidative stress
β-carotene
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
09
2020
accepted:
13
11
2020
entrez:
31
12
2020
pubmed:
1
1
2021
medline:
27
5
2021
Statut:
epublish
Résumé
The balance of the cell redox state is a key point for the maintenance of cellular homeostasis. Increased reactive oxygen species (ROS) generation leads to oxidative damage of tissues, which is involved in the development of several diseases, including autoimmune diseases. Graves' Orbitopathy (GO) is a disfiguring autoimmune-related condition associated with Graves' Disease (GD). Patients with active, moderate-to-severe GO, are generally treated with high doses intravenous glucocorticoids (ivGCs) and/or orbital radiotherapy. On the contrary, up to recently, local ointments were the treatment most frequently offered to patients with mild GO, because the risks related to ivGCs does not justify the relatively poor benefits expected in mild GO. However, a medical treatment for these patients is heavily wanted, considering that GO can progress into more severe forms and also patients with mild GO complain with an impairment in their quality of life. Thus, based on the role of oxidative stress in the pathogenesis of GO, a therapy with antioxidant agents has been proposed and a number of studies have been performed, both
Identifiants
pubmed: 33381085
doi: 10.3389/fendo.2020.608733
pmc: PMC7767963
doi:
Substances chimiques
Antioxidants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
608733Informations de copyright
Copyright © 2020 Lanzolla, Marcocci and Marinò.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298
pubmed: 29396246
Eur J Endocrinol. 2017 Feb;176(2):R101-R109
pubmed: 27760790
N Engl J Med. 2016 Oct 20;375(16):1552-1565
pubmed: 27797318
J Clin Endocrinol Metab. 2016 Dec;101(12):4834-4842
pubmed: 27610652
Mol Vis. 2013 Apr 16;19:927-34
pubmed: 23687429
Thyroid. 2015 Jul;25(7):846-50
pubmed: 26090805
Front Endocrinol (Lausanne). 2020 Jan 22;10:933
pubmed: 32038490
Ophthalmic Plast Reconstr Surg. 2014 Mar-Apr;30(2):162-7
pubmed: 24503568
Eur J Endocrinol. 2012 Feb;166(2):247-53
pubmed: 22058081
J Endocrinol Invest. 2018 Jul;41(7):815-820
pubmed: 29256181
J Pharmacol Exp Ther. 1995 Apr;273(1):509-15
pubmed: 7714806
Eur Thyroid J. 2012 Jul;1(2):80-7
pubmed: 24783001
Clin Exp Pharmacol Physiol. 2004 Nov;31(11):786-90
pubmed: 15566394
N Engl J Med. 2011 May 19;364(20):1920-31
pubmed: 21591944
Endocr Rev. 1993 Dec;14(6):747-93
pubmed: 8119236
N Engl J Med. 2017 May 4;376(18):1748-1761
pubmed: 28467880
J Clin Endocrinol Metab. 1997 Jun;82(6):1999-2002
pubmed: 9177420
Br J Dermatol. 1990 Sep;123(3):339-46
pubmed: 2206972
Clin Endocrinol (Oxf). 2011 Jan;74(1):118-24
pubmed: 21044110
Eye (Lond). 2010 Sep;24(9):1520-5
pubmed: 20300129
MedGenMed. 2006 Dec 20;8(4):60
pubmed: 17415337
Nuklearmedizin. 2015;54(5):204-10
pubmed: 26293122
J Clin Endocrinol Metab. 1991 Aug;73(2):307-13
pubmed: 1906894
Biofactors. 2003;19(3-4):155-63
pubmed: 14757966
Burns. 2009 Aug;35(5):701-6
pubmed: 19303218
J Clin Endocrinol Metab. 1998 Jan;83(1):121-4
pubmed: 9435427
J Endocrinol Invest. 2019 Apr;42(4):471-480
pubmed: 30132285
Int J Biochem Cell Biol. 2007;39(1):44-84
pubmed: 16978905
J Endocrinol Invest. 2018 Feb;41(2):193-201
pubmed: 28656526
N Engl J Med. 2020 Jan 23;382(4):341-352
pubmed: 31971679
Eur J Endocrinol. 2015 Mar;172(3):269-76
pubmed: 25661744
Pol Arch Med Wewn. 2008 Jul-Aug;118(7-8):420-5
pubmed: 18714737
Acta Endocrinol (Copenh). 1993 Oct;129(4):322-7
pubmed: 8237250
Biochem Biophys Res Commun. 2001 Nov 16;288(5):1212-7
pubmed: 11700041
Immunol Lett. 1992 Jan;31(1):35-9
pubmed: 1347751
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
J Endocrinol Invest. 2014 Aug;37(8):691-700
pubmed: 24913238
Nutrients. 2020 May 31;12(6):
pubmed: 32486488
Am J Ophthalmol. 2000 May;129(5):618-22
pubmed: 10844053
Arch Ophthalmol. 2007 Dec;125(12):1652-6
pubmed: 18071117
J Endocrinol Invest. 2011 Jul-Aug;34(7):521-7
pubmed: 21042042
Mediators Inflamm. 2005 Feb 24;2005(1):57-9
pubmed: 15770068
Curr Eye Res. 2008 May;33(5):421-7
pubmed: 18568878
Thyroid. 1999 Mar;9(3):297-303
pubmed: 10211608
Clin Endocrinol (Oxf). 2013 Aug;79(2):145-51
pubmed: 23581474
J Clin Endocrinol Metab. 1992 Apr;74(4):737-42
pubmed: 1532179
J Cardiovasc Pharmacol. 1994 Oct;24(4):648-54
pubmed: 7528848
J Endocrinol Invest. 2013 Jun;36(6):444-9
pubmed: 23587873
Br J Dermatol. 2003 Mar;148(3):544-52
pubmed: 12653748
Clin Endocrinol (Oxf). 2003 Sep;59(3):321-7
pubmed: 12919155
Curr Pharm Des. 2005;11(32):4145-51
pubmed: 16375736
Mol Vis. 2011;17:2782-8
pubmed: 22065933
Exp Eye Res. 1997 Aug;65(2):311-6
pubmed: 9268599
Int J Antimicrob Agents. 2005 Nov;26(5):343-56
pubmed: 16323269
Eur Thyroid J. 2017 Apr;6(2):113-114
pubmed: 28589094
Clin Endocrinol (Oxf). 1992 Jan;36(1):91-5
pubmed: 1532770
J Trauma. 2004 Nov;57(5):1032-7
pubmed: 15580028
Lancet. 1984 Jun 23;1(8391):1396-7
pubmed: 6145845
Clin Biochem. 2005 Jan;38(1):13-8
pubmed: 15607311
Thyroid. 2013 Jan;23(1):92-6
pubmed: 23030053